01—Abstract
Summary
Summary of the 10-K filed February 5, 2021. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, reported full-year 2020 results in this Form 10-K filed February 5, 2021.
Total revenues were $1,045.9 milliona for 2020, up from $788.1 million in 2019, driven by INGREZZA net product sales of $993.1 million. Net product sales were $994.1 million, including the first ONGENTYS sales after its September 2020 U.S. launch. The company reported net income of $407.3 million, or $4.16 per diluted share, compared with $37.0 million in 2019.
That result includes a non-cash income tax benefit of $300.6 millionb, which reflects a $296.3 million release of the valuation allowance against deferred tax assets. The filing states that beginning in 2021 the company expects to record income tax expense at an estimated rate approximating statutory rates, which would significantly reduce net income. Operating income was $163.0 million, compared with $72.3 million in 2019, after $164.5 million of acquired in-process R&D tied to the Idorsia and Takeda collaborations.
Research and development expense rose to $275.0 million and SG&A to $433.3 millionc. Cash, cash equivalents and debt securities available-for-sale totaled $1.0 billion at year-end, and net cash from operating activities was $228.5 million. In November 2020 the company repurchased $136.2 million of its 2.25% convertible senior notes due 2024 for $186.9 million in cash, leaving $381.3 million outstanding and an $18.4 million loss on extinguishment.
The pipeline includes a Phase III CAHtalyst study of crinecerfont in adult classic CAH, a Phase III KINECT-HD study of valbenazine in Huntington's disease with top-line data expected in Q4 2021, and a Phase II study of the DAAO inhibitor NBI-1065844 in negative symptoms of schizophrenia with top-line data expected in Q1 2021. The company also notified Voyager of the termination of the NBIb-1817 Parkinson's program, effective August 2, 2021, after the FDA placed a clinical hold on the RESTORE-1 study. The filing notes that the company's two largest customers represented approximately 86%d of product revenues in 2020.
02—Key points
Key Highlights
- Total revenues of $1,045.9 million in 2020, up from $788.1 million in 2019, with INGREZZA net product sales of $993.1 million.
- ONGENTYS launched in the U.S. in September 2020 and contributed $1.0 million in product sales for the year.
- Net income of $407.3 million ($4.16 diluted EPS), including a $300.6 million income tax benefit tied to a $296.3 million valuation allowance release; the company expects tax expense to resume at approximately statutory rates from 2021.
- Operating income of $163.0 million, reflecting $164.5 million of acquired in-process R&D from the Idorsia and Takeda agreements.
- Convertible senior notes reduced to $381.3 million principal after a $186.9 million cash repurchase of $136.2 million principal in November 2020, with an $18.4 million loss on extinguishment.
- Cash, cash equivalents and debt securities available-for-sale of $1.0 billion at December 31, 2020; operating cash flow of $228.5 million.
- Concentration risk: two customers represented approximately 86% of product revenue in 2020, and the company relies on third-party manufacturers and a limited number of suppliers.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Neurocrine Biosciences kept $0.39.
- Revenue$1.05B100.0%
- Cost of revenue−$10.1M1.0%
- Gross profit$1.04B99.0%
- Operating costs−$872.8M83.4%
- Operating income$163.0M15.6%
- Interest, other & tax$244.3M23.4%
- Net income$407.3M38.9%
Where FY2020 revenue went
$1.05B- Other operating costs: $439.5M, 42% of revenue
- SG&A: $433.3M, 41% of revenue
- Operating income: $163.0M, 16% of revenue
- Cost of revenue: $10.1M, 1.0% of revenue
Kept 16% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 5, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $1.05B$788.10M | +32.7% |
| Cost of Revenue | $10.10M— | — |
| Gross Profit | $1.04B— | — |
| SG&A Expenses | $433.30M$354.10M | +22.4% |
| Operating Expenses | $882.90M$715.80M | +23.3% |
| Operating Income | $163.00M$72.30M | +125.4% |
| Interest Expense | $32.80M$32.00M | +2.5% |
| Net Income | $407.30M$37.00M | +1000.8% |
| EPS (Basic) | $4.38$0.40 | +995.0% |
| EPS (Diluted) | $4.16$0.39 | +966.7% |
| Shares Outstanding (Basic) | 93.10M91.60M | +1.6% |
| Shares Outstanding (Diluted) | 97.80M95.70M | +2.2% |
05—Questions
Frequently Asked Questions
What drove the increase in Neurocrine's 2020 revenue?
INGREZZA net product sales rose $240.2 million, or 31.9%, to $993.1 million, primarily reflecting strong refill and persistency rates for existing patients. Collaboration revenue increased to $51.8 million, including a $30.0 million milestone recognized on FDA approval of AbbVie's ORIAHNN.
Why was 2020 net income so much higher than 2019?
Net income was $407.3 million versus $37.0 million in 2019, primarily because of higher INGREZZA sales and a $296.3 million release of the deferred tax valuation allowance on December 31, 2020, which produced a total income tax benefit of $300.6 million. The filing states that this benefit is non-cash and that income tax expense will be recorded from 2021 at an estimated rate approximating statutory rates, which would significantly reduce net income.
What are the main pipeline catalysts mentioned in the filing?
The filing cites Phase II top-line data for NBI-1065844 in negative symptoms of schizophrenia expected in Q1 2021, Phase III top-line data for valbenazine in Huntington's disease chorea expected in Q4 2021, and planned 2021 starts for Phase II studies of NBI-1065845 and NBI-1065846 and a Phase II study of NBI-921352 in adult focal epilepsy. In February 2021, MTPC reported positive top-line results from the J-KINECT Phase III study of valbenazine in tardive dyskinesia in Japan.
What risks did the company disclose around the Voyager collaboration?
On February 2, 2021, Neurocrine notified Voyager of its termination of the NBIb-1817 Parkinson's disease gene therapy program, effective August 2, 2021. The FDA had placed a clinical hold on the RESTORE-1 Phase II study following an IND safety report of MRI abnormalities in some participants, and the clinical implications are described as currently unknown and being evaluated. The other Voyager programs remain under the agreement.
How is the company's debt position changing?
In November 2020 Neurocrine repurchased $136.2 million principal amount of its 2.25% convertible senior notes due May 15, 2024 for $186.9 million in cash, reducing outstanding principal to $381.3 million from $517.5 million. The company may not redeem the notes before May 15, 2021, and the notes contain no financial or operating covenants.
06—Continue